The large, systemic problems facing humanity have never been clearer, nor has the need for innovative biotech solutions for these problems. The new IndieBio New York program, launching May 2020, doubles the number of companies building solutions to these problems.
Like the flagship San Francisco program, the companies accelerated in IndieBio New York will address both human and planetary health needs. The IndieBio mission to find startups whose technologies address these problems feels more urgent than ever. The new IndieBio program addresses these problems by providing early-stage biotech startups with three major areas of support as they grow their company:
- A dedicated team.
- Research facilities.
- Mentorship and community.
Meet the IndieBio New York Team
The new IndieBio New York team is excited to welcome the inaugural cohort in May.
Founding Scientist at Vertex Pharmaceuticals and co-Founder of Abpro Therapeutics.
Former CEO of SynbiCITE, the Innovation and Knowledge Center for Synthetic Biology in the United Kingdom.
Co-Founder of Bio-Start, the United Kingdom’s first life sciences accelerator.
“Working with founders of very early-stage companies, where advising and mentoring and relationship building really affect the life or death of a company, is some of the most rewarding work I’ve done. I look forward to helping founders in our teams move the needle and continue to grow.”
Founder of 4 companies including a successful exit.
Managing Director of RebelBio.
Former President and CEO at Quentis Therapeutics.
Former Senior Vice President of Investor Relations and Strategy at Regeneron Pharmaceuticals.
Executive in Residence at Columbia Technology Ventures.
“IndieBio is known for its broad portfolio of companies across all life sciences disciplines. I’m excited to work with our IndieBio cohorts to develop the next wave of life-changing technologies.”
Former Science Communications for the American Society for Microbiology.
Instructor at the community biology lab Genspace.
Co-Founder of Brooklyn Bio Inc.
“Every founder is not only an advocate for their company, but an advocate for a better future and an advocate for science. We hope that each founder in our program learns to inspire others within the biotech community and beyond.”
Previous Account Executive at Edelman London.
Former Program Associate at RebelBio.
“Our portfolio companies strive to solve major world problems. Working with companies who make crops more drought-resistant, materials more sustainable, and disease vectors less prevalent helps build a better future for everyone.”
Previous Analyst, Associate, and now Senior Associate at SOSV through nearly a decade with the firm.
“I’ve worked with deep tech companies across SOSV and am excited to apply my expertise to the new IndieBio program.”
IndieBio New York will be run out of Rockefeller University for its first year, occupying the 16th floor of the Weiss Building. The fully outfitted lab provides researchers with wet lab space, conference rooms, and common spaces for community gathering.
Mentorship and Community
The IndieBio New York program gathers founders of seed-stage companies for a 4-month intensive program. The new program applies the same cornerstone tenets of the San Francisco program: mentorship and community.
Mentors play a vital role in guiding early-stage founders. Throughout the program, mentors share their wisdom through talks to the entire group and by holding office hours for more intimate conversations.
“Relationship building is at the heart of entrepreneurship,” says Managing Director and Partner Steve Chambers. “Knowing whom to approach, and when and how, helps build the strong foundation necessary for companies to flourish. Our mentors serve the founders by sharing relationship-building tips and by becoming a part of the founders’ networks themselves.” The mentor network is further broadened by alliances with the Empire State Development and the Partnership Fund for New York City.
Community also grounds the IndieBio program. Working side-by-side for 4 months, founders learn not only from their mentors but also from each other, forming a support network that endures long after the program ends.
The team, facilities, mentorship, and community are important—and so is program adaptability. The COVID-19 pandemic requires nimble decision making to ensure all 4 components are up to IndieBio standards. Both San Francisco and New York IndieBio teams are working hard to navigate this unprecedented event and innovate program content for the founder communities they serve.